Statistics for Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey.
Total visits
views | |
---|---|
Intravitreal bevacizumab monotherapy for type-1 prethreshold, threshold, and aggressive posterior retinopathy of prematurity - 27 month follow-up results from Turkey. | 0 |
Total visits per month
views | |
---|---|
September 2023 | 0 |
October 2023 | 0 |
November 2023 | 0 |
December 2023 | 0 |
January 2024 | 0 |
February 2024 | 0 |
March 2024 | 0 |